...054298; PMID 41566776) of fully human anti-mesothelin CAR-T (huCART-meso); MSKCC intrapleural and NCI gavo-cel comparators.
...sothelin CAR-T, huCART-meso, Penn Abramson, Barber-Rotenberg, NCT03054298, MSKCC NCT02414269, gavo-cel NCT03907852, fully human scFv, MSLN, Carl June, mesot
...
51 KB (6,519 words) - 17:46, 24 May 2026
...ric antigen receptor T-cell therapy, mesothelin CAR-T, intrapleural CAR-T, MSKCC mesothelioma CAR-T, CAR-T clinical trials mesothelioma, immunotherapy mesot
..." /> The landmark phase I trial at Memorial Sloan Kettering Cancer Center (MSKCC) demonstrated a median overall survival of 23.9 months using intrapleurally
...
71 KB (9,331 words) - 05:04, 25 May 2026
...eckpoint inhibitors may be more effective than either approach alone — the MSKCC trial's 23.9-month median OS was achieved by adding pembrolizumab to rescue
...current checkpoint inhibitor therapy. This trial is actively recruiting at MSKCC.<ref name="cart_msk_next">ClinicalTrials.gov. Phase I study of M28z1XXPD1DN
...
63 KB (8,147 words) - 05:05, 25 May 2026
A key innovation of the MSKCC program is '''intrapleural delivery''' — administering CAR-T cells directly
The next-generation MSKCC trial (NCT04577326) is evaluating M28z1XXPD1DNR — a CAR engineered with a P
...
97 KB (12,342 words) - 05:05, 25 May 2026
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Phase I/II (MSKCC, NCI)
...
67 KB (8,772 words) - 23:06, 14 May 2026
